Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4

Mariñó, Zoe; Pascasio, J.M.; Sánchez-Antolín, Gloria; Baliellas, Carme; Prieto, M.; Moreno, J.M.; Carrión, J.A.; Fernández, I.; Gómez, A Ruiz; Montero, J.L.; Castro, A.; Pascual, S.; Cabezas, J.; Del, A. Arencibia C.; Calleja, J.L.; Sánchez-Ruano, Juan José; Castells, L.; Albillos, A.; Romero, María Teresa Cedena; García‐Samaniego, J.; Narváez, Isidoro; Serrano, T.; Giráldez, Álvaro; Xiol, X; Hontangas, V.; Cuervas-Mons, Valentín; Crespo, Javier; Forns, Xavier

doi:10.1016/s0168-8278(16)01632-9

Search citation statements

Order By: Relevance

Paper Sections

Select...

Efficacy In the Real‐world Setting1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2018

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, physicians now have excellent options in these patients: the 2 recommended combination regimens are the fixed‐dose of sofosbuvir/velpatasvir or sofosbuvir plus daclatasvir (Table ) . Furthermore, recent clinical trials with glecaprevir/pibrentasvir show that short duration (8 weeks) is associated with a very high response rate (98%) in treatment‐naïve genotype 2 patients, although no real‐world studies are available.…”

Section: Efficacy In the Real‐world Settingmentioning

confidence: 99%